Study links sow vaccine timing to piglet immunity in CSF

A newly published study in Frontiers in Veterinary Science adds fresh evidence that when pregnant sows are vaccinated against classical swine fever, both the vaccine used and the stage of gestation can shape what piglets receive at birth. In this head-to-head comparison, the recombinant FlagT4G vaccine outperformed the conventional C-strain vaccine on functional neutralizing immunity when sows were vaccinated at 72 days of gestation, and earlier FlagT4G vaccination at 44 days of gestation was associated with strong maternal antibody transfer and no detectable vaccine RNA in newborn piglets. (frontiersin.org)

That matters because classical swine fever remains a high-consequence disease in parts of the world where vaccination is still central to control. WOAH says vaccination can help limit spread in endemic areas, and both WOAH and APHIS describe the disease as highly contagious and reportable. Congenital infection is a particular concern, because transplacental transmission can produce weak or persistently infected piglets that help maintain virus circulation in a herd. (woah.org)

The new study was led by investigators at IRTA-CReSA, a WOAH reference laboratory for classical swine fever, alongside collaborators from Colombia and USDA’s Plum Island Animal Disease Center. In the main experiment, four sows were vaccinated at 72 days of gestation, two with C-strain and two with FlagT4G. Both vaccines triggered E2-specific binding antibodies in sows, but only FlagT4G generated high-magnitude, broadly cross-neutralizing titers. That difference carried into the offspring: piglets from FlagT4G-vaccinated sows had stronger and more consistent neutralizing responses, while piglets from C-strain-vaccinated sows had ELISA-detectable antibodies but relatively weak neutralization that declined quickly. (frontiersin.org)

The timing signal may be just as important as the platform signal. In a second experiment, two sows vaccinated with FlagT4G at 44 days of gestation developed rapid, robust antibody responses, and their piglets had no detectable CSFV RNA at any sampled time point after birth. By contrast, in the 72-day vaccination groups, vaccine-derived RNA detection in piglets was limited and transient, showing up mainly as low-level RT-qPCR signals in serum, swabs, or occasionally tonsils, without clinical signs or evidence of sustained viral dissemination. The authors argue this likely reflects residual or perinatal exposure rather than uncontrolled replication, but they also note the diagnostic implications for highly sensitive molecular testing in vaccinated populations. (frontiersin.org)

The work also builds on a broader FlagT4G development story. Earlier studies have shown the vaccine candidate can induce early protection after a single dose, and a 2024 Vaccines paper reported that FlagT4G vaccination at 44 days of gestation protected pregnant sows and prevented transplacental transmission of a highly virulent challenge strain. The vaccine’s appeal is not just immunologic. Unlike C-strain, FlagT4G is being developed as a marker, or DIVA-compatible, vaccine, and prior work has described a corresponding Flag-DIVA test intended to distinguish infected from vaccinated animals. USDA ARS has also identified FlagT4G as a development-stage vaccine candidate and reported commercial development activity with a partner in Vietnam. (mdpi.com)

There does not appear to be substantial outside commentary on this specific May 25, 2026 paper yet. Still, the results line up with longstanding concerns in swine medicine: maternally derived antibodies can be protective, but they can also complicate interpretation of serology and the timing of piglet vaccination. The study’s authors note that in the 72-day FlagT4G group, maternally derived neutralizing titers declined around the usual weaning window of 28 to 35 days, which could create a practical opportunity for piglet vaccination with less maternal antibody interference. That’s an inference about field utility, not a direct field-outcome result, but it’s a clinically relevant one. (frontiersin.org)

Why it matters: For veterinarians, diagnosticians, and herd health teams in CSF-endemic regions, this paper suggests that not all maternal antibody profiles are equally useful. A positive ELISA in piglets may not tell the whole story if neutralizing capacity is limited, and vaccine timing may influence both protection and downstream PCR interpretation. The study also reinforces why DIVA-compatible platforms remain strategically important. Traditional live vaccines like C-strain have a long track record, but their inability to distinguish vaccinated from infected animals is a known limitation in surveillance and eradication programs. (frontiersin.org)

What to watch: The next questions are whether these findings can be reproduced in larger commercial-herd studies, whether vaccination closer to farrowing increases transient RNA detection in piglets, and whether maternal immunity profiles from FlagT4G translate into cleaner vaccination schedules and surveillance workflows in the field. Regulatory progress around DIVA-compatible CSF vaccines will also be worth watching, especially in endemic markets where control programs need both protection and diagnostic clarity. (frontiersin.org)